Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Cash from Operations: 2009-2025

Historic Cash from Operations for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $27.6 million.

  • BIO-TECHNE's Cash from Operations fell 56.82% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.3 million, marking a year-over-year decrease of 17.21%. This contributed to the annual value of $287.6 million for FY2025, which is 3.82% down from last year.
  • As of Q3 2025, BIO-TECHNE's Cash from Operations stood at $27.6 million, which was down 71.91% from $98.2 million recorded in Q2 2025.
  • In the past 5 years, BIO-TECHNE's Cash from Operations ranged from a high of $122.0 million in Q2 2021 and a low of $27.6 million during Q3 2025.
  • Over the past 3 years, BIO-TECHNE's median Cash from Operations value was $75.5 million (recorded in 2024), while the average stood at $68.0 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 172.42% in 2021, then slumped by 56.82% in 2025.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Cash from Operations stood at $101.0 million in 2021, then crashed by 36.25% to $64.4 million in 2022, then climbed by 29.09% to $83.1 million in 2023, then rose by 1.48% to $84.3 million in 2024, then crashed by 56.82% to $27.6 million in 2025.
  • Its Cash from Operations stands at $27.6 million for Q3 2025, versus $98.2 million for Q2 2025 and $41.1 million for Q1 2025.